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ABSTRACT 40 
Background 41 
Metastases from primary breast cancers can involve single or multiple organs at metastatic 42 
disease diagnosis. Molecular risk factors for particular patterns of metastastic spread in a 43 
clinical population are limited.  44 
Methods 45 
A case-control design including 1,357 primary breast cancers was used to study three distinct 46 
clinical patterns of metastasis which occur within the first six months of metastatic disease: 47 
bone and visceral metasynchronous spread, bone-only, and visceral-only metastasis. Whole-48 
genome expression profiles were obtained using WG-DASL assays from formalin-fixed 49 
paraffin-embedded (FFPE) samples. A systematic protocol was developed for handling FFPE 50 
samples together with stringent data quality controls to identify robust expression profiling 51 
data. A panel of published and novel gene sets were tested for association with these specific 52 
patterns of metastatic spread and odds ratios (ORs) were calculated. 53 
Results 54 
Metasynchronous metastasis to bone and viscera was found in all intrinsic breast cancer 55 
subtypes, while IHC receptor status and specific IntClust subgroups were risk factors for 56 
visceral- or bone-only first metastases. Among gene modules, those related to proliferation 57 
increased the risk of metasynchronous metastasis (OR (95% C.I.) = 2.3 (1.1-4.8)) and 58 
visceral-only first metastasis (OR (95% C.I.) = 2.5 (1.2-5.1)) but not bone-only metastasis 59 
(OR (95% C.I.) = 0.97 (0.56-1.7)). A 21-gene module (BV) was identified in ER-positive 60 
breast cancers with metasynchronous metastasis to bone and viscera (AUC = 0.77), and its 61 
expression increased the risk of bone and visceral metasynchronous spread in this population. 62 
BV was further orthogonally validated with Nanostring nCounter in primary breast cancers, 63 
and was reproducible in their matched lymph nodes metastases and an external cohort. 64 
Conclusion 65 
This case-control study of WG-DASL global expression profiles from FFPE tumour samples, 66 
after careful quality control and RNA selection, revealed that gene modules in the primary 67 
  
3 
tumour have differing risks for clinical patterns of metasynchronous first metastases. 68 
Moreover, a novel gene module was identified as a putative risk factor for metasynchronous 69 
bone and visceral first metastatic spread, with potential implications for disease monitoring 70 
and treatment planning. 71 
 72 
Keywords: breast cancer; metasynchronous metastases; gene expression pattern. 73 
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BACKGROUND 75 
Development of metastatic breast cancer is a complex multi-step process manifesting 76 
with diverse temporal patterns involving single or multiple organs [1]. Metastases to multiple 77 
bone or visceral sites may be recorded as synchronous (reported at the same time), 78 
metasynchronous (where reported metastases are separated by a short time period, typically 79 
months) or asynchronous events with a significant delay between distant recurrences [2-4]. 80 
The median survival of patients with metastatic breast cancer is 18 to 24 months, although the 81 
range in survival spans between a few months to many years and often depends on the pattern 82 
or burden of metastatic spread. Most clinicians recommend initial treatment with 83 
chemotherapy for rapidly progressive visceral disease or in women with severe symptoms 84 
related to metastatic breast cancer [5]. Patients with bone metastases are often treated with 85 
osteoclast inhibitors, as these agents have been shown to reduce the risk of skeletal related 86 
events such as fractures, the need for surgery or radiation to bone, spinal cord compression, 87 
and hypercalcemia of malignancy.  However, patients at risk of metasynchronous metastatic 88 
spread to bone and viscera may benefit from an alternative treatment strategy at the time of 89 
first metastatic presentation. Clinicians may pursue more aggressive pursue more aggressive 90 
therapy immediately (e.g. chemotherapy instead of endocrine therapy) for patients with bone 91 
metastasis who were at high likelihood of imminent visceral metastasis, or similarly add 92 
bone-directed therapy for patients with visceral metastasis who are at high likelihood of 93 
imminent bone metastasis.  Identification of these patients at an early stage after primary 94 
diagnosis or during early metastatic disease is not well established.  95 
Various prognostic factors influence the overall survival of patients with metastatic 96 
breast cancer, including hormone receptor status and axillary lymph node status at diagnosis, 97 
previous adjuvant chemotherapy, and the number of involved organs [6, 7]. ER-positive 98 
disease has a predilection to metastasise to bone, whereas  basal-like and claudin-low breast 99 
cancers are associated with brain and lung relapses as first site of metastasis and HER2-100 
positive tumours show a predilection to cerebellar metastasis [8-14]. Transcriptional features 101 
present in the primary invasive breast carcinoma can be intrinsic to metastatic progression 102 
[15] and are currently tested in clinical trials for patient stratification for treatment regimens103 
[16, 17]. IntClust subtypes can stratify patients by disease-specific survival [18] but without 104 
attribution to specific metastatic patterns. Recently small-scale studies suggested circulating 105 
tumour-derived exosomes to be predictive for metastasis to individual bone or visceral 106 
metastatic sites [19]. It remains unclear, however, to what extent the primary tumour at the 107 
5 
time of diagnosis confers risk factors for clinical patterns of disease progression, manifesting 108 
as diverse temporal patterns of metastatic spread to single or multiple different organ sites. 109 
With the increasing use of small diagnostic biopsy procedures prior to systemic 110 
treatment for cancer patients, there are limited opportunities to also collect frozen tissue. The 111 
latter has been the prime resource for genomic analysis and subsequent publication of gene 112 
signatures for prognostic and predictive use. However, despite the potentially vast resource 113 
available within diagnostic FFPE archives, they have remained largely untapped for 114 
exploratory genome-scale biomarker studies. The quality of RNA from FFPE material has 115 
been the key limitation on its subsequent use. Whilst modifications to the extraction 116 
techniques continue to make slight improvements to the degraded RNA, there have been 117 
greater developments in array-based gene expression profiling assays and emerging 118 
technologies for transcriptome sequencing from FFPE samples [20]. The Illumina Whole-119 
Genome DASL (WG-DASL) assay is one such assay [21]. Several technical studies reported 120 
that DASL assays can produce reliable expression profiles from FFPE tumour tissue samples 121 
given adequate RNA quality, design and preprocessing of the resulting data [21-28].  122 
Here, we designed a whole-genome expression profiling study using a case-control 123 
design to include primary invasive breast cancers with three clinically observed patterns of 124 
metastatic spread: (i) metasynchronous bone and visceral metastases (within six months of 125 
first metastasis); (ii) bone only, with delayed or no visceral metastasis; and (iii) viscera only, 126 
with delayed or no bone metastasis. Given the comprehensive time and detailed organ-site 127 
information in our cohort from which cases and controls were selected, we aimed to identify 128 
intrinsic molecular features of primary breast carcinomas associated with the distinct patterns 129 
of first metastatic spread which are observed in the clinic, and in particular those with 130 
metasynchronous bone and visceral metastases.  131 
132 
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MATERIALS AND METHODS 133 
 134 
Study population, study design and patient selection  135 
The study population comprised 5,061 patients diagnosed with invasive primary breast cancer 136 
without distant metastasis at the time of diagnosis between 1975 and 2005 from Guy’s 137 
Hospital, London UK. All patients had given consent for analysis of their tumour tissues. 138 
Median follow-up was 11yrs (time between entry and exit dates in the case-control design). 139 
 Three metastatic populations were defined according to the site and specificity of 140 
recurrence: (i) first recurrence to bone only, with no other metastatic site within six months 141 
(“bone only”), (ii) first recurrence to viscera (other organs) only, with no other metastatic site 142 
within six months (“visceral only”), and (iii) recurrence to bone and viscera within a period 143 
of six months (“bone & visceral”). Bone metastasis was defined as distant metastasis to bone 144 
or bone marrow, spinal cord compression, pathological fracture or hypercalcaemia. Visceral 145 
metastasis included distant metastasis to lung, liver, brain or ascites. In the study population, 146 
1,598/5,061 (32%) developed distant metastasis: 413/1,598 (26%) to bone as first site (“bone-147 
only”), 747 (47%) to visceral as first site (“visceral-only”), and 438 (27%) to bone and 148 
visceral within a six month period (“bone & visceral”). 149 
 For each of the three metastatic populations (“visceral-only”, “bone & visceral”, 150 
“bone-only”), individually matched controls were randomly sampled using a case-control 151 
incidence based approach (Supplementary Methods). Briefly, each calendar time, T (e.g. 15th 152 
January 1999) that a case is diagnosed, one or more controls are randomly selected from the 153 
other members of the cohort who, at the time T, are still at risk of developing the outcome 154 
(distant metastasis). The controls are therefore matched to the case by time of event. A 155 
patient who is a control at one time can later become a case and/or a control again, and each 156 
of  the control series therefore includes a combination of patients still at risk which enables 157 
efficient estimation of risks in the clinical population (among 1,200 case-control sets, 75% of 158 
patients selected as controls at any calendar time did not metastasise at all, and 25% went on 159 
to have a distant metastatic event). 400 case-control sets were randomly selected for each of 160 
the three metastatic populations, giving a total of 1,200 selected case-control sets. Case-161 
control sets were then selected for tissue assessment and RNA extraction from formalin-162 
fixed, paraffin embedded (FFPE) tissue blocks. Extracted RNA was available for a total of 163 
742 case-control (1:1) pairs: 246 case-control pairs for ”visceral only” cases, 258 for “bone & 164 
visceral” cases, and 238 for “bone only” cases. An overview diagram of patient cases is 165 
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shown in Figure 1 and a detailed overview of case-control sampling, random selection and 166 
extracted case-control pairs is shown in Supplementary Figure S1A&B. Supplementary Table 167 
1 tabulates the number of cases with extracted case:control pairs (1:1), and the number of 168 
matched and unmatched cases and controls with available gene expression data. 169 
 170 
RNA extraction and gene expression profiling 171 
Formalin-fixed paraffin embedded (FFPE) samples of breast carcinomas were microdissected 172 
following tissue review. A total of 1,575 FFPE tissue blocks were assessed (H&E; 173 
Supplementary Methods). Primary tumour blocks from 1,357 patients were taken forward to 174 
micro-dissection and RNA extraction, with a total of 1,370 RNA samples (Supplementary 175 
Figure 1A). In addition, RNA was extracted from 100 matched positive axillary lymph nodes 176 
and from FFPE samples of six breast cancer cell lines. RNA extraction was outsourced to 177 
Gen-Probe Life Sciences Ltd (Manchester, UK). RNA sample quality, quantity and integrity 178 
were assessed before proceeding to Illumina HT-12 v4 BeadChips WG-DASL microarray. A 179 
detailed description of tissue selection, microdissection, RNA sample selection, hybridisation 180 
design and microarray data processing is provided in Supplementary Methods. Two gene 181 
expression data sets were produced following rigorous quality assessment: GWDb 182 
(containing primary tumour samples from 527 patients) and GWDa (containing primary 183 
tumour samples from 124 patients, after removing patients also present in GWDb). Patient 184 
characteristics for GWDb are provided by case-control series in Table 2. An overview 185 
diagram of each data set is provided in Supplementary Figure 1A. Gene expression 186 
microarray data has been deposited to Array Express E-MTAB-4003.  187 
 188 
Intrinsic subtype assignments and gene module scores 189 
PAM50 intrinsic subtype was assigned in accordance with Weigelt et al. [29] using median-190 
centred data and matching probes to centroid identifiers via gene symbol. The nearest 191 
centroid by Spearman correlation was assigned to each sample. IntClust subtypes were 192 
assigned using the iC10 package (v1.1.2) [30] for R/Bioconductor. Gene module scores for a 193 
panel of previously reported gene modules were estimated using the DART method [31] and 194 
further compared with weighted sum (weights (+1,-1) according to the direction of 195 
expression in the gene signature) (Supplementary Methods). Previously reported gene 196 
expression signatures were mapped to WG-DASL probes using Ensembl Gene ID, Entrez 197 
Gene ID or gene symbol, according to their original source (Supplementary Table S2). Where 198 
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multiple microarray probes mapped to a single Entrez Gene ID, the probe with the most 199 
variable gene expression across the datasets was used (based on standard deviation in the 200 
relevant data set). 201 
 202 
Derivation and expression summary of gene module 203 
To identify a candidate gene module for ‘bone & visceral’ metastasis (‘BV’ gene module), 204 
GWDb was reduced to ER-positive case-control pairs, and top-ranked genes were identified 205 
using an exploratory differential expression analysis of ‘bone & visceral’ and ‘No metastasis’ 206 
groups, as follows. Top-ranked genes were identified by comparing ‘bone & visceral’ vs. ‘No 207 
metastasis’ (threshold FDR-adjusted P < 0.2; Mann-Whitney U-test). This procedure resulted 208 
in a list of 21 genes (19 up, 2 down) together with the direction of differential expression 209 
between the ‘bone & visceral’ and ‘No metastasis’ groups (up, down) which defines the BV 210 
gene module. To inspect the candidate BV module within expression data sets, the expression 211 
of the gene module was summarised using a weighted sum with weights (+1,-1) according to 212 
the original direction of differential expression in the gene module. 213 
 214 
NanoString gene expression analysis 215 
For a subset of 192 samples, expression was validated for 150 selected genes by analysing 216 
total RNA (200 ng) with the nCounter platform (NanoString Technologies). Expression data 217 
were normalised using the NanoStringNorm package in R [32]. Background correction was 218 
done by subtracting the negative control probes (‘mean.2sd’). Expression values were 219 
normalised to the geometric mean of fifteen housekeeping genes. Expression values were 220 
log2 transformed and standardised within each sample (geometric mean). An expression score 221 
for the BV gene module was calculated among ER-positive samples using a weighted sum 222 
(weights (+1,-1) according to direction in the BV module) of mean-centred, standard 223 
deviation-scaled BV genes.  224 
 225 
 226 
Statistical analysis 227 
For each case-control series, conditional logistic regression models (modelling individually 228 
matched pairs) and logistic regression models (unconditional, disregarding the case-control 229 
matching) were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). For 230 
intrinsic molecular subtypes, ORs were estimated for each subtype compared with a baseline 231 
9 
subtype. IHC-derived subtypes were compared with ER-positive, HER2-negative tumours 232 
[33]. PAM50 subtypes were compared with the ‘LuminalA’ subtype (a good prognosis group 233 
[34]). IntClust subtypes were compared with the baseline IntClust3 cluster [30]. Gene module 234 
scores were scaled within each case-control series so that 95% of values lay within the range 235 
[-1,1] [35]. FDR/Benjamini-Hochberg multiple testing correction was applied to p-values 236 
across the panel of reported gene modules within each test [36]. A quartile analysis, in which 237 
cases were binned according to the quartile thresholds of the respective control series and 238 
conditional logistic regression models fitted for each quartile compared with the first quartile, 239 
showed similar trends in OR to the models which treat gene module scores as continuous 240 
variables (not shown). The Wilcoxon test for matched pairs and Mann-Whitney U test 241 
(unpaired) was used to test for differences in gene module scores between cases and controls 242 
in each series. All statistical analysis was conducted in the R environment (v3.1.2) (www.r-243 
project.org). Conditional regression models were fitted using the function clogistic() in the 244 
package Epi (v2.0) [37] (Case_Control ~ x + strata(pair.id) ). Logistic regression models 245 
were fitted using function glm(family=’binomial’) in the base package stats. A Sweave 246 
document is provided in Supplementary Methods. 247 
248 
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RESULTS 249 
Patient characteristics and sample processing 250 
 Clinico-pathological information for extracted RNA samples from 742 cases and their 251 
case-matched controls are summarised in Table 1. A rigorous inspection of extracted RNA 252 
and WG-DASL data was performed to ensure that expression profiles could be obtained 253 
across the span of storage times and inferior quality data were excluded from further analysis 254 
(Supplementary Figures S5-7). Primary tumour samples, which passed rigorous WG-DASL 255 
quality controls, were assigned to a discovery set (GWDb, 527 patients) or a smaller 256 
independent data set (GWDa, 124 patients) (Supplementary Figure S1A&B). Clinico-257 
pathological information for the three case-control series in data set GWDb is shown in Table 258 
2. Before proceeding to the analyses of the three case-control series, the clinico-pathological 259 
characteristics for each set were inspected. Patient characteristics of GWDb and GWDa 260 
retained the originally selected distribution of organ-specific metastatic spread 261 
(Supplementary Table S1A lists the number of cases for the case:control pairs (1:1), and the 262 
number of matched and unmatched cases and controls with available gene expression data). 263 
On inspection of GWDb, there were predominantly immunohistochemically (IHC)-defined 264 
ER-positive (~68%), 18% IHC HER2-positive and 32% IHC ER-negative breast cancers. 265 
Primary carcinomas were predominantly treatment naïve and invasive ductal carcinoma of 266 
no-special histological type. Patients with a ‘bone only’ pattern of first metastatic spread were 267 
more likely to report a visceral metastasis beyond a 6 month period from first metastasis 268 
(37%), than the ’visceral only’ group to a later bone metastasis (16%) (Supplementary Table 269 
S1B). The ‘visceral only’ case series had a greater proportion of grade 3 primary tumours and 270 
a smaller proportion receiving endocrine therapies than the other two case series in GWDb, 271 
while the ‘bone only’ case series had the lowest proportion of patients treated with 272 
chemotherapy (Table 2). Supplementary Figure S2 provides an illustration and descriptive 273 
summary of the temporal patterns of the single and multiple sites of metasynchronous 274 
metastatic spread present amongst all carcinomas in GWDb. 275 
 276 
 277 
Metastatic spread among breast cancer subtypes  278 
 Next we asked to what extent patients with particular molecular subtypes of breast 279 
cancer, as currently defined in the research setting, were at risk of metasynchronous bone and 280 
visceral, bone only, or visceral only patterns of first metastasis observed in the clinic. 281 
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Molecular subtypes in GWDb set were defined by the IHC status of ER/HER2 [33], assigned 282 
to the PAM50 [34] and the IntClust subtypes [18, 30]. Initially, PAM50 estimates for each 283 
tumour were compared with IHC-defined subtypes and overall a good accordance was 284 
observed: ‘Luminal A’ samples were 89% IHC ER-positive; 62% of ‘basal-like’ cases were 285 
of triple-negative phenotype (IHC ER-, PgR- and HER2-negative; TNBC); and 73% of 286 
‘HER2-enriched’ samples were IHC HER2-positive among samples with available IHC 287 
status. 288 
 Second, the molecular subtypes were tested within each case-control series using 289 
conditional logistic regression (Table 3). IHC ER-positive patients showed increased risk of 290 
‘bone only’ and decreased risk of ‘visceral only’ and ‘bone & visceral’ metastatic spread. In 291 
GWDb, breast cancer patients of the ‘HER2-enriched’ PAM50 subtype showed increased risk 292 
of ‘visceral only’, and ‘Luminal B’ of ‘bone only’, compared to the ‘Luminal A’ baseline. 293 
Patients with tumours classified as IntClust5 had an increased risk of ‘visceral-only’ spread 294 
compared to IntClust3 baseline tumours. Unconditional logistic regression models had 295 
similar OR point estimates (Table 4). The IHC ER-negative/HER2-positive subtype showed 296 
an increased risk of ‘visceral only’ and ‘bone & visceral’ spread compared to ER-297 
positive/HER2-negative carcinomas. Among IntClust classes with IntClust3 as the reference 298 
class, ‘bone & visceral’ had similar risks to the ‘visceral only’ group with the exception that 299 
IntClust2 and IntClust4 showed increased risk for ‘visceral only’ and ‘bone only’ but not 300 
‘bone & visceral’. Subtypes found to be risk factors for ‘bone & visceral’ spread were also 301 
risk factors for ‘visceral only’ or ‘bone only’ events from either the conditional or 302 
unconditional logistic regression models, indicating that molecular subtypes do not confer 303 
risks specifically for ‘bone & visceral’ events in this study.  304 
 Third, the tumour molecular subtypes of all patients in GWDb were tabulated and 305 
compared to the metastatic pattern of every patient irrespective of the case-control design, 306 
with the aim of providing a descriptive overview [30] of all primary tumours in GWDb 307 
(Figure 2). As predicted, IHC ER-negative and HER2-positive tumours were enriched for the 308 
’visceral only’ cases, and TNBC was decreased for ‘bone only’ events (Figure 2, IHC). The 309 
breakdown of IHC subtypes in the ‘bone & visceral’ group lies in between the ‘bone only‘ and 310 
‘visceral only’ groups and does not appear to be dominated by the IHC associations that would be 311 
expected for one case type or the other (‘bone only’ or ‘visceral only’). The differences were less 312 
clear across the PAM50 subgroups (Figure 2, PAM50). IntClust5 had the highest prevalence 313 
of ’visceral only’ events, whereas IntClust9 followed by IntClust6 had the most ‘bone & 314 
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visceral’ events (Figure 2, IntClust). The ‘bone only’ group were mainly ER-positive breast 315 
cancers and were predominantly assigned to IntClust3, 4 and 7 subtypes. In contrast, patients 316 
with no reported metastases were enriched for Luminal A and IntClust3 subtypes (IntClust in 317 
‘NoMetastasis’ group; χ2, P<1e-5), and ‘bone & visceral’ events were present in all IntClust 318 
subtypes (IntClust in ‘bone & visceral’; χ2, P:0.3). In summary, primary breast cancers with 319 
‘bone & visceral’ metasynchronous metastatic pattern were found across multiple molecular 320 
breast cancer subtypes in GWDb, indicating that there was no evidence of increased risk 321 
specifically for ‘bone & visceral’ events among these current breast cancer classifications 322 
(Tables 3&4). 323 
 324 
 325 
Prognostic gene modules are indicative of organ-specific metastatic predilection  326 
 327 
Several studies have reported gene expression modules indicative of particular organ-specific 328 
metastatic spread (reviewed in [38, 39]). We therefore asked whether some of those modules 329 
were also activated across our three metastatic groups and to what extent the activation of 330 
individual gene modules in the primary tumour is a risk for the clinically observed patterns of 331 
metasynchronous ‘bone & visceral’, ‘bone only’, or ‘visceral only’ first metastasis. Primary 332 
tumour expression modules were selected if they were previously reported to be associated 333 
with: (i) features of proliferation, cell motility, presence of stem-cell-like cells and 334 
immune/lymphocytic infiltration, and (ii) organ-specific metastasis (Supplementary Table 335 
S2). 336 
 The gene modules were each tested as a risk for each pattern of metastatic spread 337 
within GWDb using conditional logistic regression (Figure 3A) and logistic regression on 338 
complete case-control pairs (Figure 3B). In addition, logistic regression models were fitted 339 
using all controls and all cases (to avoid discarding both samples from a pair due to missing 340 
data from GWDb), and using ER-stratified data with or without discarding samples from ER-341 
mismatching pairs (Supplementary Figure S3). Pairwise correlation of gene modules 342 
confirms that proliferation signatures are highly correlated in this data set and there is also 343 
correlation between other modules previously reported to represent metastasis to individual 344 
sites and between immune-related signatures (Figure 3C), consistent with other studies [35, 345 
40]. Expression of proliferation-associated genes have been repeatedly shown to be 346 
associated with the prognosis of ER-positive breast cancers [41]. In our study, gene modules 347 
13 
related to proliferation increased the risk of metasynchronous bone and visceral metastasis 348 
(for example, conditional logistic regression model of PTEN module, OR (95% C.I.) = 2.3 349 
(1.1-4.8); Supplementary Table S3) and ‘visceral only’ first metastasis (PTEN, OR (95% 350 
C.I.) = 2.5 (1.2-5.1); Supplementary Table S3) but not ‘bone only’ metastasis (PTEN, OR351 
(95% C.I.) = 0.97 (0.56-1.7); Supplementary Table S3). Risk associations were observed by 352 
logistic regression modelling within ER-positive or ER-negative tumours (Supplementary 353 
Table S3, Supplementary Figure 3A).  354 
In addition, with the alternative aim of providing a descriptive summary of gene 355 
module activation among all breast carcinomas present in GWDb, two exploratory analyses 356 
were performed irrespective of the case-control design: tumours with each pattern of 357 
metastatic spread were compared with all tumours with no metastasis using a logistic 358 
regression model (Supplementary Figure S3B), and time-to-metastasis to individual sites 359 
(lung, liver, bone, brain) was modelled irrespective of the patterns of first metastatic spread 360 
or any other metastases at any time during follow-up (Supplementary Figure S3C&D). In 361 
agreement with other studies, neither the logistic regression with reference to tumours with 362 
no metastasis nor the time-to-event analyses can be interpreted in the standard 363 
epidemiological sense estimating associations between exposures and outcomes, due to the 364 
sample selection methods employed in this study. These models are presented here as 365 
exploratory hypothesis-generating tools only with no inference implied for the breast cancer 366 
population. Metastasis to any site was associated with proliferation signatures irrespective of 367 
ER status. (Supplementary Figure S3C). A number of gene modules indicated nominal 368 
significance but would not pass a multiple testing correction (Supplementary Fig 3). In IHC 369 
ER-negative breast cancers TGF- response [42] and hypoxia response gene sets [43] were 370 
activated in carcinomas with ‘visceral only’ metastases compared with those which did not 371 
metastasise (Supplementary Figure S3B), while TGF- response and hypoxia response gene 372 
sets showed an association with time-to-lung metastasis (Supplementary Figure S3D). A stem 373 
cell module which is a strong indicator of short relapse in TNBC [44] was present in ER-374 
negative breast cancers with ‘visceral only’ metastases, and a module related to intermediate 375 
tissue burden and progression from stemness/basal-like cells [45] was associated with the 376 
‘visceral only’ and ‘bone & visceral’ groups, while the low tissue-burden/basal-like module 377 
(derived from metastatic cells from tissues with low metastatic burden [45]) was 378 
underexpressed in the ‘bone only’ group compared with cancers with no reported metastases. 379 
Taken together, while we were able to recapitulate previously reported associations between 380 
14 
gene signatures and metastasis to bone or visceral organs within our study, there were no 381 
specific gene module with distinctive risk factors for the clinically observed 382 
metasynchronous ‘bone & visceral’ spread group. 383 
384 
385 
386 
A prognostic gene module for metasynchronous metastatic spread 387 
388 
As the question remains whether any molecular features could be identified in 389 
primary tumours at the time of diagnosis for metasynchronous ‘bone & visceral’ metastases, 390 
we then aimed to extract specific gene expression patterns associated with the ‘bone & 391 
visceral’ metastatic group. In order to control for interactions between ER status and 392 
metastatic group, the discovery set (GWDb) was stratified by ER status by removing those 393 
case-control pairs with differing IHC ER status (Supplementary Methods). We proceeded 394 
with a total of 175 ER-positive breast cancer patients. Exploratory differential expression 395 
analysis was performed between the ‘bone & visceral’ group and tumours with no metastasis 396 
and the top-ranked genes (FDR-adjusted p < 0.2; see Methods) was taken forward for further 397 
exploratory analysis (Supplementary Table S4). ROC curve analysis revealed an AUC of 398 
0.77 for a 21 gene set for the ‘bone & visceral’ metastatic group (termed ‘BV’; Figure 4A, 399 
Supplementary Table S4), in comparison to an AUC of 0.66 and 0.56 for ‘visceral only’ and 400 
‘bone only’, respectively, while combining all three series indicated an overall AUC of 0.83 401 
for any metastatic site (Supplementary Figure S4). 402 
The risk of ‘bone & visceral’ spread from BV gene module was next estimated using 403 
the ‘bone & visceral’ case-control series within GWDb and GWDa (Supplementary Table 404 
S5). A significant risk of ‘bone & visceral’ spread was observed within GWDb (OR (95% 405 
C.I.) = 6.0 (3.1-12.2). In the independent data set GWDa, OR estimate were also positive (OR406 
(95% C.I.) = 1.9 (0.38-9.7), and a shift towards increased BV scores in the cases compared to 407 
the controls were found (Mann-Whitney U, p=0.3), however due to small sample size it was 408 
not significant (Supplementary Table S5). Together these results indicated that this BV gene 409 
module might confer an increased risk of the ‘bone & visceral’ pattern of metastatic spread.  410 
To further explore the relevance of our BV gene module, orthogonal validation of the 411 
discovery was obtained on three levels: (i) with NanoString, by testing the expression of 412 
these genes in a representative subset of 192 samples, in which BV scores were highly 413 
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concordant with WG-DASL values (Figure 4B; Pearson’s correlation, cor=0.78, P<1e-4); (ii) 414 
the expression of the BV gene set was reproduced in matched lymph node metastases within 415 
our cohort (Figure 4C); and (iii) we investigated the gene expression of the BV module in an 416 
external data set of lymph node metastases from breast cancers with known metastatic 417 
disease [46]. The BV gene module exhibited increased expression in the lymph node 418 
metastases of those patients with a ‘bone & visceral’ pattern of first metastatic spread 419 
compared with ‘visceral only’ (Figure 4D; Mann-Whitney U test, P:0.04) and ‘bone only’ 420 
(Figure 4D; Mann-Whitney U test, P:0.1, n.s.) groups. These results are in line with our 421 
exploratory analyses and together are the first demonstration towards developing an intrinsic 422 
risk factor in primary breast cancer for metasynchronous bone and visceral first distant 423 
recurrences. Inspection of the genes comprising the candidate BV module indicated an 424 
enrichment for association with condensing chromosomes and the kinetochore 425 
(Supplementary Figure S8). 426 
 427 
 428 
DISCUSSION 429 
 430 
Metastasis represents the major cause of death for breast cancer patients. Over the last few 431 
years, numerous molecular-based prognostic tests of varying specificity have emerged, 432 
indicating that primary breast carcinomas display expression profiles associated with organ-433 
specific dissemination, however few studies have addressed synchronous and 434 
metasynchronous patterns of metastatic spread [47]. Treatment strategies and monitoring for 435 
patients could potentially be tailored if prediction of single or multi-organ metastasis could be 436 
estimated at an early stage. As a step towards this goal, this study estimates potential risks for 437 
particular patterns of metastatic spread associated with intrinsic subtypes and gene modules 438 
in the primary tumour. A gene expression module present in primary invasive carcinomas 439 
associated with concurrent or short-term delays between the development of bone and 440 
visceral metastasis was identified and validated in an independent series of lymph node 441 
metastases.  442 
 Predilection for metastatic spread for breast cancer has previously been associated with 443 
gene modules enriched in the primary tumour. A common feature of these are markers of cell 444 
proliferation, such as the GENE70, PTEN, the centrosomal kinase AURKA [48, 49] as well as 445 
multiple processes related to chromosomal instability including CIN70 [50]. In this study, we 446 
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found that a gene module containing components of the kinetochore (CENPO, SPC25, 447 
CASC5, SKA3, CENPE; GO CC term ‘kinetochore’) was associated with the occurrence of 448 
metasynchronous bone and visceral metastases within six months of the first metastasis. The 449 
regulation of genes encoding kinetochore components has been hypothesised to drive 450 
chromosomal instability [51], whereby the upregulation of kinetochore genes may reflect the 451 
activation of a cell division program [52]. We speculate that the association of this gene 452 
module with rapid multitropic bone and visceral spread after first metastasis points to a 453 
mechanism of chromosomal instability, enabling the development of subclones and selection 454 
of metastatic tumour cells for invasion and adaption at multiple bone and visceral sites. Gene 455 
modules related to proliferation or mammary stem cells might be expected to influence the 456 
synchronicity of multiple metastases, and were indeed found to be significant risks for 457 
multiple bone and visceral first metastases. 458 
 Limitations of this study include the imposition of a timeline which defines  459 
metasynchronous metastases: for example, in our datasets a change in the definition of 460 
metasynchronous from 6-month to 12-month would have led 10% of ‘bone only’ and 5% of 461 
‘visceral only’ to have been considered metasynchronous (Supplementary Figure 2A), and 462 
other definitions of metasynchronicity could be imposed which may affect the estimated risks 463 
for each case type. The AUC for the BV signature was higher for all metastasis than for 464 
metasynchronous bone and visceral metastasis: from the point of view of clinical translation, 465 
further work would need to establish whether BV or other putative signatures for patterns of 466 
metastatic spread could add value over existing signatures such as Oncotype or Mammaprint 467 
[16, 17]. 468 
 Metastasis is a complicated, multi-step process and our understanding of the multiple 469 
factors involved is still partial. In the last decade, genomic profiling has attempted to fill this 470 
knowledge gap, however these studies have primarily used fresh-frozen tissue, had restricted 471 
numbers of primary and metastatic cases, and incomplete information on the site and time to 472 
development of the metastatic spread. This has limited the utility and clinical applicability of 473 
these modules. There is evidence that some tumours have a predilection for colonising 474 
specific tissues in clinical populations (e.g. [10]), while animal model and recent next 475 
generation sequencing studies also support a role for subclonal adaptations to the metastatic 476 
niche (e.g. [53]). In this study, we focused on the tumour as one part of this complex 477 
metastatic cascade which is close to clinical diagnostic practise and patient management. We 478 
hypothesised that intrinsic subtypes and gene modules confer risk of particular patterns of 479 
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metastatic spread in some tumours. We addressed this question by designing a case-control 480 
study for particular patterns of metastatic spread.  481 
 Pre-clinical models have contributed to our understanding of metastastic spread but 482 
they might not capture many of the processes which are important in a clinical setting - 483 
including alterations to the immune system or incorporation of specific latency periods to 484 
study multi-organ metastatic spread in parallel - and many gene signatures originate from 485 
ER-negative cell line and PDX models. Multiple lines of evidence indicate that intrinsic 486 
subtypes and gene modules have different metastatic potential within clinical populations [18, 487 
54, 55]. We sought to address whether gene modules could confer risk for specific temporal 488 
patterns of metastatic spread using a large tumour archive with detailed clinical follow up. An 489 
efficient case-control design is required given that multiple breast cancer subtypes and 490 
metastatic patterns are present in any clinical population. This study therefore focused on 491 
three specific patterns of metastatic spread based on epidemiological observations from the 492 
same clinical population [56].  493 
 As recently shown by Iddawela et al. [28] and others, the WG-DASL platform together 494 
with stringent quality control and data processing steps can produce reliable results from 495 
FFPE breast tumour tissue. Here, by starting with a well characterised cohort of 5,061 496 
patients with long-term follow up of whom 1,598 developed metastasis, we have created a 497 
well-annotated and sufficiently large cohort to investigate molecular risk factors for single 498 
and multiple organotropic metasynchronous metastatic disease. While many samples were 499 
excluded during the quality control steps, the processed gene expression data sets enabled an 500 
investigation of gene expression modules as risk factors for specific patterns of first 501 
metastatic spread. 502 
 The use of an incidence-based case-control design ensured that non-metastasising 503 
primary tumour samples were also included from the same range of calendar dates of 504 
diagnosis, and enabled efficient estimation of effects in a standard clinical population. Cunha 505 
et al. [57] recently reported using a case-control design to estimate the effect of ALK1 506 
expression in frozen breast tumours as a molecular risk factor for metastatic spread. Here, our 507 
use of an incidence-based case-control design enabled the estimation of genome-wide 508 
molecular risk factors for three clinically observed patterns of first metastatic spread (bone 509 
only, visceral only, or bone and visceral within a six month time period). Further work on 510 
patterns of long-term disease progression may focus on a more defined population, such as 511 
18 
ER-positive/HER2-negative or high grade tumours, and make use of appropriate platforms 512 
for assaying fewer FFPE tumour samples from a stratified clinical population. 513 
Patients at risk of metasynchronous bony and visceral metastases could potentially 514 
profit from closer disease monitoring and may benefit from a more radical bisphosphonate 515 
and chemotherapeutic combination treatment strategy up front in the metastatic setting. In 516 
ER-positive disease the benefits of hormonal therapy in managing visceral metastases from 517 
breast cancer are much lower than those offered by chemotherapy. Conversely, Perez et al. 518 
[58] suggest that, for patients with bone metastases, efforts should be made to select the least519 
aggressive therapy to avoid excessive toxicity. Progress towards the optimisation of disease 520 
monitoring and treatment strategies fundamentally requires a better understanding of risks 521 
which could be estimated at primary diagnosis, together with an improved understanding of 522 
additional emerging risks as breast cancers progress to a metastatic setting (for example, 523 
establishment of a metastatic niche). Initiatives such as AURORA, a large multinational, 524 
collaborative metastatic breast cancer molecular screening programme [59] will further shed 525 
light on our knowledge of whether the gene expression patterns found in primary breast 526 
cancers is similar to those in metastatic material. This would add to our understanding of the 527 
metastatic process as well as guide treatment regimens for metastatic breast cancer. A liver-528 
selective gene module was among the set of gene modules, where these genes were under-529 
expressed in primary tumours from patients who subsequently developed liver metastases, 530 
but displayed high expression in the liver metastases [46]. We observed the low-level 531 
expression of these 17 genes in ER-positive cancers, which metastasised to the liver. Of note, 532 
this inverse correlation in the direction of transcript levels of some genes between primary 533 
tumours and metastases was not unique to this gene module, but was also seen in another 534 
gene module associated with infiltration of the blood-brain barrier [60] and has also been 535 
recently reported in ovarian cancers [61]. Due to the scarcity of available samples, a clear 536 
biological conclusion cannot be drawn about such inverse correlation and we hypothesise that 537 
the process of adaption to the new microenvironment or development of the pre-metastatic 538 
niche [62, 63] favours those primary tumour traits. Ultimately, larger cohorts with matched 539 
primary and metastatic lesions are required to elucidate the clinical relevance of these 540 
transcriptional changes after primary diagnosis. 541 
542 
543 
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CONCLUSIONS 545 
546 
In conclusion, by analysing gene expression profiles in a large cohort of well characterised 547 
primary breast carcinomas and lymph node metastases in patients with long-term follow-up 548 
and detailed metastatic spread information, we were able to identify patterns informative of 549 
multiple organotropic metasynchronous metastatic spread. Further investigations are 550 
necessary in order to tease out the contributing components, which could be relevant for 551 
tailoring systemic therapeutic regimens, monitoring response or resistance to therapy, and 552 
warranting close imaging/biomarker followup with the institution of early intervention 553 
strategies as required. These genomewide expression data across extensive case-control series 554 
will provide a useful resource facilitating further studies of the biology and clinical relevance 555 
of single and metasynchronous metastatic spread, and might enable rational personalised 556 
treatment strategies to be developed for patients at risk of bone or visceral metastasis with 557 
subsequent metasynchronous metastasis.  558 
559 
560 
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FFPE: formalin-fixed, paraffin-embedded; ER: estrogen receptor; PgR: progesterone 563 
receptor; HER2: human epidermal growth factor receptor 2. IHC: Immunohistochemistry. 564 
TNBC: triple-negative breast cancer. BH: Benjamini-Hochberg method for multiple testing 565 
correction. 566 
 567 
 568 
 569 
DECLARATIONS 570 
 571 
Ethical Approval and Consent to Participate 572 
Ethical approval was obtained from King's Health Partners Cancer Biobank, London, UK, a 573 
HTA Licensed (12121) and NHS REC approved Tissue Bank (12/EE/0493). All patient 574 
samples were pseudoanonymised by the Biobank. 575 
 576 
Consent for publication 577 
Not applicable 578 
 579 
Availability of data and material 580 
Gene expression microarray data has been deposited to Array Express E-MTAB-4003. 581 
 582 
Competing interests 583 
The authors declare no competing interests. 584 
 585 
Funding 586 
Patient samples and data were provided by King’s Health Partners Cancer Biobank, which is 587 
supported by the Department of Health via the National Institute for Health Research (NIHR) 588 
comprehensive Biomedical Research Centre award and the Experimental Cancer Centre at 589 
King’s College London. KL was supported by the CRUK and EPSRC Comprehensive 590 
Cancer Imaging Centre at KCL and UCL (C1519/A10331 and C1519/A16463) and European 591 
Union Framework Programme 7 HEALTH-2010 grant entitled ‘Imagint’ (grant number 592 
259881). AG and AT were supported by the Breast Cancer Now Research Unit (former 593 
Breakthrough Breast Cancer Research) funding at King's College London and by the 594 
  
21 
National Institute for Health Research Biomedical Research Centre based at Guy's and St 595 
Thomas' NHS Foundation Trust and King's College London.  596 
 597 
 598 
Authors' contributions 599 
 600 
KL participated in data analysis, interpretation, and helped to draft the manuscript. 601 
EP performed the WG-DASL assays and participated in data analysis.
 
602 
CN participated in acquisition of RNA samples. 603 
AM participated in acquisition of follow-up data.
 
604 
KO participated in data analysis and archiving.
 
605 
AT participated in study concept and design, and data interpretation.
 
606 
SK participated in design and data acquisition for the independent cohort.
 
607 
IH participated in design and data acquisition for the independent cohort.
 
608 
JZ participated in interpretation of the data.
 
609 
HZ participated in interpretation of the data.
 
610 
RB participated in NanoString data acquisition.
 
611 
MD participated in NanoString data acquisition and critical reading of the manuscript.
 
612 
TN participated in study concept and design, and data interpretation.
 
613 
SEP participated in study concept and design, and acquisition of RNA samples. 
 
614 
PP participated in study concept and design, and data interpretation.
 
615 
LH designed the case-control series, and participated in the design of data analyses and 616 
interpretation.
 
617 
CEG participated in study concept and design, acquisition of RNA samples, and helped to 618 
draft the manuscript.
 
619 
AG participated in study concept and design, design of data analyses, and wrote the 620 
manuscript. 621 
AP conceived the study, participated in study design and interpretation, and wrote the 622 
manuscript. 623 
All authors read and approved the final manuscript. 624 
 625 
 626 
 627 
22 
Acknowledgements 628 
The authors thank Dr. O. Agbaje for assistance with case-control selection and description of 629 
the protocol, Dr. S. Irshad for helpful comments on clinical perspectives, and anonymous 630 
reviewers for their constructive and insightful comments. 631 
632 
633 
634 
635 
REFERENCES 636 
637 
1. Kimbung S, Loman N, Hedenfalk I: Clinical and molecular complexity of breast cancer638 
metastases. Semin Cancer Biol 2015, 35:85-95.639 
2. Plunkett TA, Smith P, Rubens RD: Risk of complications from bone metastases in breast640 
cancer: implications for management. Eur J Cancer 2000, 36(4):476-482.641 
3. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity.642 
Clinical cancer research : an official journal of the American Association for Cancer643 
Research 2006, 12(20 Pt 2):6243s-6249s.644 
4. Marlow R, Honeth G, Lombardi S, Cariati M, Hessey S, Pipili A, Mariotti V, Buchupalli B,645 
Foster K, Bonnet D et al: A novel model of dormancy for bone metastatic breast cancer646 
cells. Cancer Res 2013, 73(23):6886-6899.647 
5. Wilcken N, Hornbuckle J, Ghersi D: Chemotherapy alone versus endocrine therapy alone648 
for metastatic breast cancer. Cochrane Database of Systematic Reviews 2003.649 
6. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi650 
JM, Ettore F, Birtwisle-Peyrottes I et al: Prognostic factors in 1,038 women with651 
metastatic breast cancer. Annals of oncology : official journal of the European Society for652 
Medical Oncology / ESMO 2008, 19(12):2012-2019.653 
7. Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R: Significance of estrogen and654 
progesterone receptors, disease-free interval, and site of first metastasis on survival of655 
breast cancer patients. Cancer 1985, 56(7):1696-1700.656 
8. Lai R, Dang CT, Malkin MG, Abrey LE: The risk of central nervous system metastases657 
after trastuzumab therapy in patients with breast carcinoma. Cancer 2004, 101(4):810-658 
816.659 
9. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM:660 
Genomic analysis identifies unique signatures predictive of brain, lung, and liver661 
relapse. Breast Cancer Research and Treatment 2012, 132:523-535.662 
10. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO,663 
Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010,664 
28(20):3271-3277.665 
11. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD,666 
Castiglione-Gertsch M, Coates AS, Goldhirsch A et al: Patterns of Recurrence and667 
outcome according to breast cancer subtypes in lymph node-negative disease: results668 
from international breast cancer study group trials VIII and IX. J Clin Oncol 2013,669 
31(25):3083-3090.670 
12. Sihto H, Lundin J, Lundin M, Lehtimaki T, Ristimaki A, Holli K, Sailas L, Kataja V,671 
Turpeenniemi-Hujanen T, Isola J et al: Breast cancer biological subtypes and protein672 
expression predict for the preferential distant metastasis sites: a nationwide cohort673 
study. Breast cancer research : BCR 2011, 13(5):R87.674 
23 
13. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, Foekens Ja, Martens JWM:675 
Subtypes of breast cancer show preferential site of relapse. Cancer Research 2008,676 
68:3108-3114.677 
14. Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J,678 
Niland JC, Weeks JC et al: Impact of hormone receptor status on patterns of recurrence679 
and clinical outcomes among patients with human epidermal growth factor-2-positive680 
breast cancer in the National Comprehensive Cancer Network: a prospective cohort681 
study. Breast cancer research : BCR 2012, 14(5):R129.682 
15. Mittempergher L, Saghatchian M, Wolf DM, Michiels S, Canisius S, Dessen P, Delaloge S,683 
Lazar V, Benz SC, Tursz T et al: A gene signature for late distant metastasis in breast684 
cancer identifies a potential mechanism of late recurrences. Molecular Oncology 2013,685 
7:987-999.686 
16. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Jr., Dees687 
EC, Perez EA, Olson JA, Jr. et al: Prospective Validation of a 21-Gene Expression Assay688 
in Breast Cancer. N Engl J Med 2015, 373(21):2005-2014.689 
17. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E,690 
Causeret S, DeLorenzi M et al: 70-Gene Signature as an Aid to Treatment Decisions in691 
Early-Stage Breast Cancer. N Engl J Med 2016, 375(8):717-729.692 
18. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG,693 
Samarajiwa S, Yuan Y et al: The genomic and transcriptomic architecture of 2,000 breast694 
tumours reveals novel subgroups. Nature 2012:1-7.695 
19. Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H,696 
Kohsaka S, Di Giannatale A, Ceder S et al: Tumour exosome integrins determine697 
organotropic metastasis. Nature 2015, 527:329-335.698 
20. Sinicropi D, Qu K, Collin F, Crager M, Liu ML, Pelham RJ, Pho M, Dei Rossi A, Jeong J,699 
Scott A et al: Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk700 
using formalin-fixed paraffin-embedded tumor tissue. PLoS ONE 2012, 7(7):e40092.701 
21. April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J, Cox D, Jones W,702 
Rubio R, Holton K et al: Whole-genome gene expression profiling of formalin-fixed,703 
paraffin-embedded tissue samples. PLoS ONE 2009, 4(12):e8162.704 
22. Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, Bouzyk M, Sledge GW, Jr.,705 
Moreno CS, Leyland-Jones B: Optimization of RNA extraction from FFPE tissues for706 
expression profiling in the DASL assay. BioTechniques 2008, 44(3):417-423.707 
23. Ravo M, Mutarelli M, Ferraro L, Grober OM, Paris O, Tarallo R, Vigilante A, Cimino D, De708 
Bortoli M, Nola E et al: Quantitative expression profiling of highly degraded RNA from709 
formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide710 
microarrays. Lab Invest 2008, 88(4):430-440.711 
24. Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL,712 
McCullough AE, Dueck AC, Chen B, April CS et al: Expression profiling of formalin-fixed713 
paraffin-embedded primary breast tumors using cancer-specific and whole genome gene714 
panels on the DASL(R) platform. BMC Med Genomics 2010, 3:60.715 
25. Saleh A, Zain RB, Hussaini H, Ng F, Tanavde V, Hamid S, Chow AT, Lim GS, Abraham716 
MT, Teo SH et al: Transcriptional profiling of oral squamous cell carcinoma using717 
formalin-fixed paraffin-embedded samples. Oral Oncol 2010, 46(5):379-386.718 
26. Waddell N, Cocciardi S, Johnson J, Healey S, Marsh A, Riley J, da Silva L, Vargas AC, Reid719 
L, kConFab et al: Gene expression profiling of formalin-fixed, paraffin-embedded720 
familial breast tumours using the whole genome-DASL assay. J Pathol 2010, 221(4):452-721 
461.722 
27. Mittempergher L, de Ronde JJ, Nieuwland M, Kerkhoven RM, Simon I, Rutgers EJT,723 
Wessels LFa, Van't Veer LJ: Gene expression profiles from formalin fixed paraffin724 
embedded breast cancer tissue are largely comparable to fresh frozen matched tissue.725 
PloS ONE 2011, 6:e17163.726 
28. Iddawela M, Rueda OM, Klarqvist M, Graf S, Earl HM, Caldas C: Reliable gene expression727 
profiling of formalin-fixed paraffin-embedded breast cancer tissue (FFPE) using cDNA-728 
  
24 
mediated annealing, extension, selection, and ligation whole-genome (DASL WG) assay. 729 
BMC Med Genomics 2016, 9(1):54. 730 
29. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho 731 
JS: Breast cancer molecular profiling with single sample predictors: a retrospective 732 
analysis. The Lancet Oncology 2010, 11(4):339-349. 733 
30. Ali HR, Rueda OM, Chin SF, Curtis C, Dunning MJ, Aparicio SA, Caldas C: Genome-734 
driven integrated classification of breast cancer validated in over 7,500 samples. Genome 735 
Biol 2014, 15(8):431. 736 
31. Jiao Y, Lawler K, Patel GS, Purushotham A, Jones AF, Grigoriadis A, Tutt A, Ng T, 737 
Teschendorff AE: DART: Denoising Algorithm based on Relevance network Topology 738 
improves molecular pathway activity inference. BMC Bioinformatics 2011, 12:403. 739 
32. Waggott DM: NanoStringNorm: Normalize NanoString miRNA and mRNA Data. In., 740 
vol. R package version 1.1.21. http://CRAN.R-project.org/package=NanoStringNorm; 2015. 741 
33. Lips EH, Mulder L, De Ronde JJ, Mandjes IaM, Koolen BB, Wessels LFa, Rodenhuis S, 742 
Wesseling J: Breast cancer subtyping by immunohistochemistry and histological grade 743 
outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy 744 
response. Breast Cancer Research and Treatment 2013, 140:63-71. 745 
34. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, 746 
Hu Z et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin 747 
Oncol 2009, 27(8):1160-1167. 748 
35. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart 749 
M, Michiels S, Sotiriou C: Gene modules and response to neoadjuvant chemotherapy in 750 
breast cancer subtypes: a pooled analysis. J Clin Oncol 2012, 30(16):1996-2004. 751 
36. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and 752 
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B 753 
(Statistical Methodology) 1995, 57:289-300. 754 
37. Carstensen B, Plummer M, Laara E, Hills M: Epi: A package for Statistical Analysis in 755 
Epidemiology. R package version 2.0. http://CRAN.R-project.org/package=Epi. 2016. 756 
38. Nguyen DX, Bos PD, Massague J: Metastasis: from dissemination to organ-specific 757 
colonization. Nat Rev Cancer 2009, 9(4):274-284. 758 
39. Vanharanta S, Massague J: Origins of metastatic traits. Cancer Cell 2013, 24(4):410-421. 759 
40. Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM: The Role of 760 
Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: 761 
A Gene Expression-Based Meta-Analysis. Clinical cancer research : an official journal of 762 
the American Association for Cancer Research 2016, 22(24):6039-6050. 763 
41. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS: Challenges translating breast cancer 764 
gene signatures into the clinic. Nat Rev Clin Oncol 2012, 9(1):58-64. 765 
42. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, 766 
Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M et al: Molecular definition of breast 767 
tumor heterogeneity. Cancer Cell 2007, 11:259-273. 768 
43. Lu X, Yan CH, Yuan M, Wei Y, Hu G, Kang Y: In vivo dynamics and distinct functions of 769 
hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer 770 
Res 2010, 70(10):3905-3914. 771 
44. Soady KJ, Kendrick H, Gao Q, Tutt A, Zvelebil M, Ordonez LD, Quist J, Tan DW, Isacke 772 
CM, Grigoriadis A et al: Mouse mammary stem cells express prognostic markers for 773 
triple-negative breast cancer. Breast cancer research : BCR 2015, 17:31. 774 
45. Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, 775 
Balakrishnan S, Wang CY et al: Single-cell analysis reveals a stem-cell program in human 776 
metastatic breast cancer cells. Nature 2015, 526(7571):131-135. 777 
46. Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog 778 
L, Carlsson L, Einbeigi Z, Lidbrink E et al: Transcriptional Profiling of Breast Cancer 779 
Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse 780 
Outcome in Luminal A Primary Breast Cancer. Clinical cancer research : an official 781 
journal of the American Association for Cancer Research 2015:1078-0432.CCR-1015-0487-. 782 
  
25 
47. Ho VK, Gijtenbeek JM, Brandsma D, Beerepoot LV, Sonke GS, van der Heiden-van der Loo 783 
M: Survival of breast cancer patients with synchronous or metachronous central 784 
nervous system metastases. Eur J Cancer 2015. 785 
48. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, 786 
Piccart M, Sotiriou C: Biological processes associated with breast cancer clinical outcome 787 
depend on the molecular subtypes. Clinical cancer research : an official journal of the 788 
American Association for Cancer Research 2008, 14(16):5158-5165. 789 
49. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C: A 790 
three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer 791 
Inst 2012, 104(4):311-325. 792 
50. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z: A signature of chromosomal 793 
instability inferred from gene expression profiles predicts clinical outcome in multiple 794 
human cancers. Nat Genet 2006, 38:1043-1048. 795 
51. Yuen KW, Montpetit B, Hieter P: The kinetochore and cancer: what's the connection? 796 
Curr Opin Cell Biol 2005, 17(6):576-582. 797 
52. Thiru P, Kern DM, McKinley KL, Monda JK, Rago F, Su KC, Tsinman T, Yarar D, Bell 798 
GW, Cheeseman IM: Kinetochore genes are coordinately up-regulated in human tumors 799 
as part of a FoxM1-related cell division program. Mol Biol Cell 2014, 25(13):1983-1994. 800 
53. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, 801 
Alexandrov LB, Larsimont D, Davies H et al: Subclonal diversification of primary breast 802 
cancer revealed by multiregion sequencing. Nat Med 2015, 21(7):751-759. 803 
54. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de 804 
Rijn M, Jeffrey SS et al: Gene expression patterns of breast carcinomas distinguish 805 
tumor subclasses with clinical implications. Proceedings of the National Academy of 806 
Sciences of the United States of America 2001, 98:10869-10874. 807 
55. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, 808 
Haibe-Kains B et al: Gene expression profiling in breast cancer: understanding the 809 
molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 810 
98(4):262-272. 811 
56. Purushotham A, Shamil E, Cariati M, Agbaje O, Muhidin A, Gillett C, Mera A, Sivanadiyan 812 
K, Harries M, Sullivan R et al: Age at diagnosis and distant metastasis in breast cancer--a 813 
surprising inverse relationship. Eur J Cancer 2014, 50(10):1697-1705. 814 
57. Cunha SI, Bocci M, Lovrot J, Eleftheriou N, Roswall P, Cordero E, Lindstrom L, Bartoschek 815 
M, Haller BK, Pearsall RS et al: Endothelial ALK1 Is a Therapeutic Target to Block 816 
Metastatic Dissemination of Breast Cancer. Cancer Res 2015, 75(12):2445-2456. 817 
58. Perez JE, Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, 818 
Rodriguez R, Cuevas MA, Alvarez LA: Bone-only versus visceral-only metastatic pattern 819 
in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncologico 820 
Cooperativo del Sur. Am J Clin Oncol 1990, 13(4):294-298. 821 
59. Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos 822 
P, Saini KS, Sotiriou C et al: The AURORA initiative for metastatic breast cancer. Br J 823 
Cancer 2014, 111(10):1881-1887. 824 
60. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, 825 
Gerald WL, Foekens JA et al: Genes that mediate breast cancer metastasis to the brain. 826 
Nature 2009, 459(7249):1005-1009. 827 
61. Brodsky AS, Fischer A, Miller DH, Vang S, MacLaughlan S, Wu HT, Yu J, Steinhoff M, 828 
Collins C, Smith PJ et al: Expression profiling of primary and metastatic ovarian tumors 829 
reveals differences indicative of aggressive disease. PLoS ONE 2014, 9(4):e94476. 830 
62. Lu X, Kang Y: Organotropism of breast cancer metastasis. Journal of Mammary Gland 831 
Biology and Neoplasia 2007, 12:153-162. 832 
63. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, Li P, Li M, Wang X, Zhang C 833 
et al: Microenvironment-induced PTEN loss by exosomal microRNA primes brain 834 
metastasis outgrowth. Nature 2015. 835 
836 
26 
FIGURE LEGENDS 837 
838 
Figure 1. Overview diagram of cases and gene expression data sets. For each metastatic 839 
population (“visceral only”, “bone & visceral”, “bone only”) 400 cases were sampled, and 840 
three possible controls were matched to each case by calendar time of event. A random 841 
sample of case-control sets was taken forward to tissue assessment for RNA extraction 842 
(Supplementary Methods). Extracted RNA was available for a total of 742 case-control (1:1) 843 
pairs, comprising a total of 1,277 individual patients. A detailed overview of patients and 844 
samples included in the design and in the gene expression data sets is shown in 845 
Supplementary Figure S1A, B. 846 
847 
Figure 2. Distribution of three metastatic groups across breast cancer subtypes within 848 
the dataset GWDb. Barplots illustrate the proportion of immunohistochemically defined 849 
(IHC), prediction analysis of microarray 50 (PAM50) and IntClust breast cancer subtypes 850 
present in each metastatic group (a) and the proportion of each metastatic group assigned to 851 
IHC, PAM50 and IntClust subtypes (b). The patient number for each group is shown on the 852 
top of each column. ER estrogen receptor, HER2 human epidermal growth factor receptor, 853 
TNBC triple-negative breast cancer 854 
Figure 3. Forestplots of log(OR) estimated from univariate conditional logistic 855 
regression and logistic regression models of illustrative gene modules in GWDb for each 856 
metastatic group. A. Conditional logistic regression (matched pairs). B. Logistic regression 857 
using complete case-control pairs. Alternative grey and green bars indicate the broad 858 
categorisation of illustrative gene modules (Proliferation’, ‘Immune’, etc.) as shown in the 859 
module labels on the left of the plot. C. Heatmap of pairwise correlation for a panel of gene 860 
modules (Pearson correlation, ‘complete’ clustering; irrespective of case type or case-control 861 
status). Gene modules are listed in Supplementary Table S2.  862 
Figure 4. BV module for metasynchronous metastatic spread. A. Discovery of the BV 863 
module. BV module scores, shown as density plots for each metastatic group in the ER-864 
positive case-control paired breast cancer cases from the discovery set (GWDb) together with 865 
the corresponding ROC curve for the ‘bone & visceral’ group. B. Estimated BV expression 866 
score based on NanoString quantification compared with those obtained from the WG-DASL 867 
  
27 
platform. C. Correlation plot displaying the BV gene set in primary tumours and their 868 
matched lymph node metastases. Dots are colour coded according to the metastatic groups. 869 
D. Boxplot of BV module scores in lymph node metastases of the GSE46141 data, displayed 870 
according to their reported patterns of first metastatic spread.  871 
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 872 
TABLE LEGENDS 873 
 874 
Tables 1 and 2. Patient characteristics for case-control series. 875 
Table 1. Patients with available high-quality RNA sample. 876 
Table 2. Patients present in the discovery set (GWDb). 877 
 878 
Table 3. Estimated ORs for molecular subtype representations based on conditional 879 
logisitic regression. IHC-derived subtypes were compared with ER-positive, HER2-negative 880 
tumours. PAM50 subtypes were compared with the ‘LuminalA’ subtype. IntClust subtypes 881 
were compared with the baseline IntClust3 cluster. ORs were calculated from conditional 882 
logistic regression models. 883 
 884 
Table 4. Estimated ORs for molecular subtype representations based on logisitic 885 
regression. IHC-derived subtypes were compared with ER-positive, HER2-negative 886 
tumours. PAM50 subtypes were compared with the ‘LuminalA’ subtype. IntClust subtypes 887 
were compared with the baseline IntClust3 cluster. ORs were calculated from logistic 888 
(unmatched) regression models, to avoid missing data where one sample of a pair is not 889 
available in GWDb.  890 
 891 
  892 
29 
ADDITIONAL DATA FILES 892 
893 
Supplementary Methods (PDF). Detailed description of tissue preparation including 894 
microtomy, de-waxing and staining, micro-dissection and preparation of materials, and gene 895 
expression processing and quality control. 896 
Supplementary Figures (PDF). Contains Supplementary Figures S1-S8. 897 
Supplementary Tables (XLSX). Contains Supplementary Tables S1-S2, S4-S5. 898 
Supplementary Table S3 (XLSX). Contains Supplementary Table S3. 899 
900 
901 
902 
Table 1. Patient characteristics in the case-control series: patients with extracted RNA sample
V cases V controls BV cases BV controls B cases B controls
Number of patients 246 232 258 245 238 222
Number (%)
Age at hist. diagnosis Median (years) 57.1 51.5 55.7 51.0 55.9 51.2
Grade 1 11 (4%) 33 (14%) 7 (3%) 36 (15%) 20 (8%) 20 (9%)
2 81 (33%) 89 (38%) 113 (44%) 127 (52%) 114 (48%) 97 (44%)
3 135 (55%) 87 (38%) 122 (47%) 62 (25%) 81 (34%) 88 (40%)
Unknown 19 (8%) 23 (10%) 16 (6%) 20 (8%) 23 (10%) 17 (8%)
ER IHC status Positive 147 (60%) 160 (69%) 162 (63%) 174 (71%) 188 (79%) 158 (71%)
Negative 99 (40%) 72 (31%) 96 (37%) 71 (29%) 50 (21%) 64 (29%)
PR status Positive 97 (39%) 121 (52%) 116 (45%) 131 (53%) 146 (61%) 113 (51%)
Negative 149 (61%) 111 (48%) 142 (55%) 114 (47%) 92 (39%) 109 (49%)
HER2 status Positive 58 (24%) 35 (15%) 55 (21%) 30 (12%) 35 (15%) 23 (10%)
Negative 108 (44%) 102 (44%) 116 (45%) 98 (40%) 108 (45%) 107 (48%)
Unknown 80 (33%) 95 (41%) 87 (34%) 117 (48%) 95 (40%) 92 (41%)
Tumour size <= 2 cm 96 (40%) 113 (49%) 99 (38%) 136 (56%) 101 (42%) 117 (53%)
>2 cm 146 (60%) 113 (49%) 155 (60%) 101 (41%) 133 (56%) 99 (45%)
Unknown – – 6 (3%) 4 (2%) 8 (3%) 4 (2%) 6 (3%)
Lymph nodes positive 0 51 (21%) 97 (42%) 61 (24%) 109 (44%) 61 (26%) 103 (46%)
1–3 74 (30%) 81 (35%) 64 (25%) 80 (33%) 70 (29%) 64 (29%)
4+ 74 (30%) 28 (12%) 81 (31%) 28 (11%) 64 (27%) 29 (13%)
Unknown 47 (19%) 26 (11%) 52 (20%) 28 (11%) 43 (18%) 26 (12%)
Invasive subtype NOS/no special type 217 (88%) 189 (81%) 219 (85%) 206 (84%) 196 (82%) 189 (85%)
Ductal - mucinous 1 (0%) 3 (1%) 4 (2%) 2 (1%) 1 (0%) 4 (2%)
Ductal - tubular – – 6 (3%) 1 (0%) 7 (3%) 3 (1%) 3 (1%)
Ductal - other 6 (2%) 3 (1%) 1 (0%) 3 (1%) 1 (0%) 3 (1%)
Lobular - classical 14 (6%) 23 (10%) 19 (7%) 22 (9%) 29 (12%) 13 (6%)
Lobular - pleomorphic 3 (1%) 2 (1%) 6 (2%) 3 (1%) 3 (1%) 4 (2%)
Lobular - other 2 (1%) 3 (1%) 3 (1%) 2 (1%) 4 (2%) 1 (0%)
Other 3 (1%) 3 (1%) 5 (2%) – – 1 (0%) 5 (2%)
Surgery type (any time) Breast conserving 58 (24%) 80 (34%) 70 (27%) 82 (33%) 64 (27%) 72 (32%)
Breast conserving +mastectomy 53 (22%) 28 (12%) 56 (22%) 32 (13%) 37 (16%) 27 (12%)
Mastectomy 106 (43%) 110 (47%) 99 (38%) 120 (49%) 115 (48%) 114 (51%)
Unknown 29 (12%) 14 (6%) 33 (13%) 11 (4%) 22 (9%) 9 (4%)
Radiotherapy (adj/neo) Yes 168 (68%) 140 (60%) 197 (76%) 126 (51%) 194 (82%) 125 (56%)
No 78 (32%) 92 (40%) 61 (24%) 119 (49%) 44 (18%) 97 (44%)
Hormone treatment (adj/neo) Yes 204 (83%) 120 (52%) 230 (89%) 130 (53%) 218 (92%) 114 (51%)
No 42 (17%) 112 (48%) 28 (11%) 115 (47%) 20 (8%) 108 (49%)
Chemotherapy Neo-adj only – – 3 (1%) 3 (1%) 67 (27%) 8 (3%) 3 (1%)
Neo-adj and adj 6 (2%) 1 (0%) 9 (3%) 1 (0%) 1 (0%) 2 (1%)
Adj only 146 (59%) 85 (37%) 150 (58%) 2 (1%) 101 (42%) 67 (30%)
No 94 (38%) 143 (62%) 96 (37%) 175 (71%) 128 (54%) 150 (68%)
Hist.: histological assessment, ER: IHC estrogen receptor status determined by immunohistochemical assessment, PR progesterone receptor, HER2 human epidermal 
growth factor receptor 2, adj adjuvant, neo neoadjuvant
Table 2. Patient characteristics in the case-control series: patients in the discovery cohort GWDb
V cases V controls BV cases BV controls B cases B controls Case series
Number of patients 105 82 106 86 98 90 χ2 p
Age at hist. diag. Median (years) 55.4 52.0 52.5 50.3 55.9 48.8
Grade 1 3 (3%) 12 (15%) 3 (3%) 13 (15%) 8 (8%) 7 (8%)
2 27 (26%) 32 (39%) 44 (42%) 47 (55%) 44 (45%) 42 (47%)
3 68 (65%) 34 (41%) 55 (52%) 19 (22%) 38 (39%) 37 (41%)
Unknown 7 (7%) 4 (5%) 4 (4%) 7 (8%) 8 (8%) 4 (4%) 18.2 0.01
ER IHC status Positive 57 (54%) 52 (63%) 69 (65%) 62 (72%) 77 (79%) 65 (72%)
Negative 48 (46%) 30 (37%) 37 (35%) 24 (28%) 21 (21%) 25 (28%) 13.3 0.001
PR status Positive 39 (37%) 40 (49%) 53 (50%) 56 (65%) 59 (60%) 51 (57%)
Negative 66 (63%) 42 (51%) 53 (50%) 30 (35%) 39 (40%) 39 (43%) 10.9 0.004
HER2 status Positive 31 (30%) 13 (16%) 22 (21%) 13 (15%) 15 (15%) 11 (12%)
Negative 44 (42%) 38 (46%) 51 (48%) 41 (48%) 45 (46%) 42 (47%)
Unknown 30 (29%) 31 (38%) 33 (31%) 32 (37%) 38 (39%) 37 (41%) 7.0 0.1
Tumour size <= 2 cm 41 (39%) 39 (48%) 39 (37%) 44 (51%) 38 (39%) 47 (52%)
>2 cm 64 (61%) 42 (51%) 65 (61%) 38 (44%) 60 (61%) 41 (46%) 0.1 1.0
Unknown – – 1 (1%) 2 (2%) 4 (5%) – – 2 (2%)
Lymph nodes positive 0 15 (14%) 33 (40%) 21 (20%) 32 (37%) 24 (24%) 39 (43%)
1–3 34 (32%) 29 (35%) 31 (29%) 28 (33%) 30 (31%) 30 (33%)
4+ 37 (35%) 10 (12%) 40 (38%) 11 (13%) 26 (27%) 10 (11%)
Unknown 19 (18%) 10 (12%) 14 (13%) 15 (17%) 18 (18%) 11 (12%) 6.1 0.4
Invasive subtype NOS/no special type 96 (91%) 70 (85%) 85 (82%) 73 (85%) 82 (84%) 81 (90%)
Ductal - mucinous – – 2 (2%) 1 (1%) – – 1 (1%) 1 (1%)
Ductal - tubular – – – – 1 (1%) 3 (3%) 2 (2%) 1 (1%)
Ductal - other 1 (1%) 1 (1%) 1 (1%) – – – – 3 (3%)
Lobular - classical 5 (5%) 5 (6%) 7 (7%) 9 (10%) 12 (12%) 2 (2%)
Lobular - pleomorphic 1 (1%) 1 (1%) 6 (6%) – – – – 1 (1%)
Lobular - other – – 2 (2%) 2 (2%) 1 (1%) 1 (1%) – –
Other 2 (2%) 1 (1%) 1 (1%) – – – – 1 (1%) 1.7 0.4 †
Surgery type (any time) Breast conserving 30 (29%) 34 (41%) 35 (33%) 43 (50%) 31 (32%) 39 (43%)
Breast conserving +
mastectomy
17 (16%) 11 (13%) 19 (18%) 7 (8%) 15 (15%) 13 (14%)
Mastectomy 47 (45%) 33 (40%) 41 (39%) 30 (35%) 43 (44%) 35 (39%)
Unknown 11 (10%) 4 (5%) 11 (10%) 6 (7%) 9 (9%) 3 (3%) 1.2 1.0
Radiotherapy (adj/neo) Yes 79 (75%) 52 (63%) 84 (79%) 55 (64%) 82 (84%) 59 (66%)
No 26 (25%) 30 (37%) 22 (21%) 31 (36%) 16 (16%) 31 (34%) 2.2 0.3
Hormone treatment (adj/neo) Yes 84 (80%) 38 (46%) 97 (92%) 57 (66%) 92 (94%) 51 (57%)
No 21 (20%) 44 (54%) 9 (8%) 29 (34%) 6 (6%) 39 (43%) 11.0 0.004
Chemotherapy Neo-adj only – – 2 (2%) 2 (2%) 1 (1%) 5 (5%) 3 (3%)
Neo-adj and adj 4 (4%) – – 4 (4%) 1 (1%) 1 (1%) – –
Adj only 65 (62%) 33 (40%) 67 (63%) 24 (28%) 43 (44%) 28 (31%)
No 36 (34%) 47 (57%) 33 (31%) 60 (70%) 49 (50%) 59 (66%) 8.7 0.01 ‡
Metastatic events in control series No mets, 64 (78%)
V = 8, BV = 8, B = 2
No mets, 66 (77%)
V = 10, BV = 5, B = 5
No mets, 69 (77%)
V = 4, BV = 10, B = 7
†ductal versus lobular, ‡any versus no chemotherapy. Abbreviations as for Table 1
n,  paired n,  informative n,  paired n,  informative n,  paired n,  informative n,  paired n,  informative 
Note:
  with 
 controls. and cases between permitted were Duplicates design. by series case each within duplicates no are There uniq"). ("n, series control each within de-duplicated were patients here, design; by series control a within duplicated were patients of number small A test. unpaired an is This 
missingEntries  excluded. were variable independent the in values  
n,  uniq n,  uniq n,  uniq n,  uniq 
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